![](https://i0.wp.com/bioengineer.org/wp-content/uploads/2025/02/Enhancing-Prostate-Cancer-Treatment-RAD51-Biomarker-as-a-Complement-to.jpeg?fit=700%2C394&ssl=1)
Enhancing Prostate Cancer Treatment: RAD51 Biomarker as a Complement to Next-Generation Sequencing
A recent study led by the Vall d’Hebron Institute of Oncology (VHIO) has revealed significant findings regarding the application of RAD51 protein testing as an adjunct to next-generation sequencing (NGS) in the treatment of metastatic prostate cancer. This …